NCCN announces awards for improvement initiatives for chronic myeloid leukaemia: Plymouth Meeting, Pennsylvania Saturday, April 25, 2026, 10:00 Hrs [IST] The National Comprehensiv ...

Chronic myeloid leukemia (CML) is also known as chronic myelogenous leukemia. In this type of cancer, the bone marrow produces too many white blood cells. If the disease isn’t effectively treated, it ...

Newly published data suggests most patients are opting for second- or third-generation tyrosine kinase inhibitors instead of a generic form of imatinib. Patients with chronic myelogenous leukemia (CML ...

Mendus AB ("Mendus" publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies for myeloid blood cancers, today announced that the first patient has been enrolled in the VITAL-CML trial, w ...

LONDON--(BUSINESS WIRE)--The global chronic myelogenous leukemia (CML) therapeutics market size is poised to grow by USD 1.74 billion during 2019-2023, according to a new report by Technavio, ...

Please provide your email address to receive an email when new articles are posted on . It has been eight years since imatinib was approved as the first oral tyrosine kinase inhibitor indicated for ...

Enliven Therapeutics Inc. (NASDAQ:ELVN) is one of the 11 Stocks With 3x-5x Returns This Year. Enliven Therapeutics has seen ...

An advocate discusses vital patient-provider conversations to promote the best care for individuals with chronic myeloid leukemia. Receiving a diagnosis of chronic myeloid leukemia (CML) can be ...

The life expectancy of patients with recently diagnosed chronic myeloid leukemia (CML) is now approaching that of the general population, which is an important message for physicians to convey to ...

Oncology Research Program (ORP) today announced funding awards for quality improvement initiatives in CML. The NCCN ORP will oversee these projects, with funding provided by Novartis Pharmaceuticals ...